STOCK TITAN

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Nurix Therapeutics (NRIX), a clinical stage biopharmaceutical company focused on targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in five major investor conferences in November 2024. The company's leadership team, including CEO Arthur T. Sands, CFO Hans van Houte, and CBO Jason Kantor, will attend:

- Truist BioPharma Symposium (NY, Nov 7)
- UBS Healthcare Conference (CA, Nov 12)
- Stephens Biotechnology Virtual Fireside Chats (Nov 14)
- Stifel Healthcare Conference (NY, Nov 18)
- Jefferies London Healthcare Conference (UK, Nov 21)

Webcasts for the UBS, Stifel, and Jefferies conferences will be available on Nurix's website for 30 days post-event.

Nurix Therapeutics (NRIX), un'azienda biofarmaceutica in fase clinica focalizzata su farmaci per la modulazione mirata delle proteine per il trattamento di cancro e malattie infiammatorie, ha annunciato la sua partecipazione a cinque importanti conferenze per investitori nel novembre 2024. Il team di leadership dell'azienda, incluso il CEO Arthur T. Sands, il CFO Hans van Houte e il CBO Jason Kantor, parteciperà a:

- Truist BioPharma Symposium (NY, 7 novembre)
- UBS Healthcare Conference (CA, 12 novembre)
- Stephens Biotechnology Virtual Fireside Chats (14 novembre)
- Stifel Healthcare Conference (NY, 18 novembre)
- Jefferies London Healthcare Conference (Regno Unito, 21 novembre)

I webcast per le conferenze UBS, Stifel e Jefferies saranno disponibili sul sito web di Nurix per 30 giorni dopo l'evento.

Nurix Therapeutics (NRIX), una empresa biofarmacéutica en etapa clínica centrada en medicamentos para la modulación dirigida de proteínas para el cáncer y enfermedades inflamatorias, ha anunciado su participación en cinco importantes conferencias de inversores en noviembre de 2024. El equipo de liderazgo de la empresa, incluido el CEO Arthur T. Sands, el CFO Hans van Houte y el CBO Jason Kantor, asistirá a:

- Truist BioPharma Symposium (NY, 7 de noviembre)
- UBS Healthcare Conference (CA, 12 de noviembre)
- Stephens Biotechnology Virtual Fireside Chats (14 de noviembre)
- Stifel Healthcare Conference (NY, 18 de noviembre)
- Jefferies London Healthcare Conference (Reino Unido, 21 de noviembre)

Los webcasts de las conferencias de UBS, Stifel y Jefferies estarán disponibles en el sitio web de Nurix durante 30 días después del evento.

Nurix Therapeutics (NRIX)는 암 및 염증 질환을 위한 표적 단백질 조절 약물에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 11월에 다섯 개의 주요 투자자 회의에 참가할 예정이라고 발표했습니다. CEO Arthur T. Sands, CFO Hans van Houte, CBO Jason Kantor를 포함한 회사의 리더십 팀이 참석할 예정입니다:

- Truist BioPharma Symposium (NY, 11월 7일)
- UBS Healthcare Conference (CA, 11월 12일)
- Stephens Biotechnology Virtual Fireside Chats (11월 14일)
- Stifel Healthcare Conference (NY, 11월 18일)
- Jefferies London Healthcare Conference (영국, 11월 21일)

UBS, Stifel 및 Jefferies 회의의 웹캐스트는 이벤트 후 30일 동안 Nurix 웹사이트에서 제공됩니다.

Nurix Therapeutics (NRIX), une entreprise biopharmaceutique en phase clinique axée sur les médicaments de modulation des protéines ciblées pour le cancer et les maladies inflammatoires, a annoncé sa participation à cinq grandes conférences pour investisseurs en novembre 2024. L'équipe dirigeante de l'entreprise, comprenant le PDG Arthur T. Sands, le CFO Hans van Houte et le CBO Jason Kantor, assistera aux événements suivants :

- Truist BioPharma Symposium (NY, 7 novembre)
- UBS Healthcare Conference (CA, 12 novembre)
- Stephens Biotechnology Virtual Fireside Chats (14 novembre)
- Stifel Healthcare Conference (NY, 18 novembre)
- Jefferies London Healthcare Conference (Royaume-Uni, 21 novembre)

Les webcasts des conférences UBS, Stifel et Jefferies seront disponibles sur le site Web de Nurix pendant 30 jours après l'événement.

Nurix Therapeutics (NRIX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Proteinmodulationsmedikamente für Krebs und entzündliche Erkrankungen spezialisiert hat, hat seine Teilnahme an fünf großen Investorenkonferenzen im November 2024 angekündigt. Das Führungsteam des Unternehmens, darunter CEO Arthur T. Sands, CFO Hans van Houte und CBO Jason Kantor, wird teilnehmen an:

- Truist BioPharma Symposium (NY, 7. November)
- UBS Healthcare Conference (CA, 12. November)
- Stephens Biotechnology Virtual Fireside Chats (14. November)
- Stifel Healthcare Conference (NY, 18. November)
- Jefferies London Healthcare Conference (UK, 21. November)

Webcasts für die Konferenzen UBS, Stifel und Jefferies werden 30 Tage nach der Veranstaltung auf der Website von Nurix verfügbar sein.

Positive
  • None.
Negative
  • None.

SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in November:

  • Truist BioPharma Symposium (New York, NY)
    • Panel discussion: Thursday, November 7, 2024, from 10:30 – 11:20 a.m. ET
  • UBS Healthcare Conference (Rancho Palos Verdes, CA)
    • Fireside chat: Tuesday, November 12, 2024, from 5:00 – 5:35 p.m. PT
  • Stephens Biotechnology Virtual Fireside Chats
    • Fireside chat: Thursday, November 14, 2024, from 2:30 – 3:15 p.m. ET
  • Stifel Healthcare Conference (New York, NY)
    • Presentation: Monday, November 18, 2024, from 4:45 – 5:15 p.m. ET
  • Jefferies London Healthcare Conference (London, U.K.)
    • Presentation: Thursday, November 21, 2024, from 11:30 – 11:55 a.m. GMT

Presentations and fireside chats at the UBS Healthcare Conference, Stifel Healthcare Conference, and Jefferies London Healthcare Conference will be webcast live and may be accessed via links in the Investors section of the Nurix website under Events and Presentations. The archived webcasts will be available on the Nurix website for 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Contacts:

Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com


FAQ

What investor conferences will Nurix Therapeutics (NRIX) attend in November 2024?

Nurix will participate in five conferences: Truist BioPharma Symposium (Nov 7), UBS Healthcare Conference (Nov 12), Stephens Biotechnology Virtual Fireside Chats (Nov 14), Stifel Healthcare Conference (Nov 18), and Jefferies London Healthcare Conference (Nov 21).

Which Nurix (NRIX) conference presentations will be available via webcast?

The presentations at UBS Healthcare Conference, Stifel Healthcare Conference, and Jefferies London Healthcare Conference will be webcast live and available on Nurix's website for 30 days after each event.

When is Nurix Therapeutics (NRIX) presenting at the Jefferies London Healthcare Conference?

Nurix will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024, from 11:30 to 11:55 a.m. GMT.

Who will represent Nurix (NRIX) at the investor conferences in November 2024?

Nurix will be represented by Arthur T. Sands (President and CEO), Hans van Houte (CFO), and Jason Kantor (Chief Business Officer).

Nurix Therapeutics, Inc.

NASDAQ:NRIX

NRIX Rankings

NRIX Latest News

NRIX Stock Data

1.58B
69.46M
1.45%
98.27%
13.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO